Why the study?
Although HDL has a significant impact on pulmonary artery vasoreactivity and prognosis in PAH, the exact mechanism by which it exerts its effect in the pulmonary circulation remains under investigation.
What is the role of HDL cholesterol as a marker of disease severity and prognosis in patients with pulmonary arterial hypertension?
What is the role of HDL cholesterol as a marker of disease severity and prognosis in patients with pulmonary arterial hypertension?
This review highlights the emerging role of HDL cholesterol as a potential marker of disease severity and prognosis in pulmonary arterial hypertension.
Answers are grounded in this paper and cite their sources.
May indicate disease severity and prognosis in PAH; hypothesis-generating and requires prospective validation before clinical adoption.
The impact of high-density lipoprotein (HDL) cholesterol on the development of atherosclerosis and diseases of systemic circulation has been well documented both in experimental and registry studies. Recent discoveries in pulmonary arterial hypertension (PAH) revealed a significant impact of HDL on pulmonary artery vasoreactivity and patients' prognosis. The vasoprotective activity of HDL primarily involves vascular endothelium that also plays a central role in pulmonary arterial hypertension (PAH) pathobiology. However, the exact mechanism in which this lipoprotein fraction exerts its effect in pulmonary circulation is still under investigation. This paper reviews potential vasoprotective mechanisms of HDL in pulmonary circulation and presents current clinical reports on the role of HDL in PAH patients.
No takes yet. Share an insight, caveat, or question.
Jonas et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: